Results 31 to 40 of about 16,704,778 (257)
Prognosis and Staging of AL Amyloidosis [PDF]
Acta Haematologica, 2020 The treatment options for systemic light chain amyloidosis (AL) are currently widening in an unprecedented way, brought about by an expanding arsenal of anti-myeloma therapy as well as by novel approaches to target toxic light chains and, most recently, deposited amyloid directly.
Tobias Dittrich +3 more
openaire +2 more sources
Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis
Amyloid: Journal of Protein Folding Disorders, 2021 In 2012, the International Society of Amyloidosis (ISA) established the criteria for assessment of haematologic response to treatment in light chain (AL) amyloidosis [1].
G. Palladini +10 more
semanticscholar +1 more source
Difficulties in diagnosis of primary AL-amyloidosis
Онкогематология, 2021 Objective of the study: analysis of AL-amyloidosis (AL-A) diagnostics in real clinical practice and to determine the main approaches for the earlier detection of this disease.Materials and methods.
V. A. Khyshova +3 more
doaj +1 more source
Role of mutations and post-translational modifications in systemic AL amyloidosis studied by cryo-EM
Nature Communications, 2021 Systemic AL amyloidosis is a rare disease that is caused by the misfolding of immunoglobulin light chains (LCs). Potential drivers of amyloid formation in this disease are post-translational modifications (PTMs) and the mutational changes that are ...
L. Radamaker +17 more
semanticscholar +1 more source
Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis
Swiss Medical Weekly, 2020 Systemic amyloidosis is a heterogeneous group of diseases associated with protein misfolding into insoluble beta-sheet rich structures that deposit extracellularly in different organs, eventually compromising their function.
Rahel Schwotzer +42 more
doaj +1 more source
Severe Obstructive Cholestasis and Hypercalcemia Caused by Light-Chain Amyloidosis: A Case Report [PDF]
Iranian Journal of Medical Sciences, 2022 Gastrointestinal amyloidosis is a condition caused by the deposition of extracellular protein fragments. It can be associated with complex and diverse pathways and can have numerous manifestations and etiologies.
Zahra Davoudi +3 more
doaj +1 more source
High-Throughput Precision Phenotyping of Left Ventricular Hypertrophy with Cardiovascular Deep Learning [PDF]
, 2021 Left ventricular hypertrophy (LVH) results from chronic remodeling caused by a broad range of systemic and cardiovascular disease including hypertension, aortic stenosis, hypertrophic cardiomyopathy, and cardiac amyloidosis. Early detection and characterization of LVH can significantly impact patient care but is limited by under-recognition of ...
arxiv +1 more source
Tensorial tomographic Fourier Ptychography with applications to muscle tissue imaging [PDF]
Tensorial tomographic Fourier Ptychography with applications to
muscle tissue imaging, Adv. Photon. 6(2), 026004 (2024), 2023 We report Tensorial tomographic Fourier Ptychography (ToFu), a new non-scanning label-free tomographic microscopy method for simultaneous imaging of quantitative phase and anisotropic specimen information in 3D. Built upon Fourier Ptychography, a quantitative phase imaging technique, ToFu additionally highlights the vectorial nature of light.
arxiv +1 more source
Dysregulation of miRNAs In AL Amyloidosis [PDF]
Blood, 2010 Abstract Abstract 4648 Bone marrow plasma cells (BMPC) were purified from aspirates obtained from patients with AL amyloidosis using anti-CD138 immunomagnetic beads, and from controls. Expression levels of micro RNAs (miRNAs) were compared by microarray.
Carl O'Hara +5 more
openaire +4 more sources
Blood, 2020 Although no therapies are currently approved for light chain (AL) amyloidosis, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) is considered a standard treatment for newly diagnosed patients.
G. Palladini +19 more
semanticscholar +1 more source